Related Experiment Video

Updated: Aug 8, 2026

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
06:14

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Published on: June 11, 2017

Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a

A Hirata1, M Igarashi, H Yamaguchi

  • 1Department of Laboratory Medicine, Yamagata University School of Medicine, 2-2-2, Iida-nishi, Yamagata 990-9585, Japan.

British Journal of Pharmacology
|January 5, 2001
PubMed

Insights

Nifedipine effectively reduces balloon-induced intimal thickening and vascular smooth muscle cell proliferation in rats. This suggests nifedipine may prevent atherosclerotic plaque progression and restenosis after angioplasty.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Cell Biology

Background:

  • Atherosclerosis involves intimal thickening and vascular smooth muscle cell (VSMC) proliferation.
  • Balloon angioplasty can induce intimal hyperplasia, a process relevant to restenosis.
  • Identifying agents that inhibit VSMC proliferation is crucial for cardiovascular disease management.

Purpose of the Study:

  • To investigate the in vivo and in vitro effects of nifedipine on intimal thickening and VSMC proliferation.
  • To determine if nifedipine can suppress atherogenic processes relevant to restenosis.
  • To elucidate the cellular mechanisms underlying nifedipine's potential anti-atherosclerotic effects.

Main Methods:

  • In vivo study: Sprague-Dawley rats received continuous nifedipine administration via osmotic pumps after balloon injury.
  • In vitro study: Cultured rat VSMCs were treated with nifedipine to assess proliferation markers.
  • Analysis included neointima/media area ratios, [(3)H]-thymidine incorporation, protein content, and Western blotting for key signaling proteins (ERK, MEK, Pyk2) and PCNA.

Main Results:

  • Nifedipine significantly reduced neointima/media area ratios in a dose-dependent manner in vivo, without affecting blood pressure or lipid levels.
  • In vitro, nifedipine decreased VSMC proliferation, evidenced by reduced [(3)H]-thymidine incorporation and total protein.
  • Nifedipine dose-dependently inhibited phosphorylation of ERK1/2, MEK1/2, and Pyk2, and suppressed PCNA levels in both in vitro and in vivo models.

Conclusions:

  • Nifedipine exhibits a significant inhibitory effect on intimal thickening induced by balloon injury.
  • The drug attenuates intimal VSMC proliferation through mechanisms involving key signaling pathways.
  • These findings suggest nifedipine's potential therapeutic role in preventing atherosclerotic plaque progression and restenosis post-angioplasty.

More Related Videos

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels08:46

Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels

Published on: March 22, 2024

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...